- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Westbrook Today
By the People, for the People
Aster Capital Management DIFC Ltd Trims IDEXX Laboratories Stake
Institutional investor reduces position in veterinary diagnostics company by 95%
Published on Mar. 2, 2026
Got story updates? Submit your updates here. ›
Aster Capital Management DIFC Ltd, an institutional investor, has lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 95% during the third quarter, according to a recent SEC filing. The firm now owns 195 shares of the company's stock, down from 3,930 shares previously.
Why it matters
IDEXX Laboratories is a leading provider of diagnostic products and services for the animal health, water testing, and food safety markets. The reduction in Aster Capital's stake could signal a shift in investor sentiment towards the company, though it's unclear if this is part of a broader trend or an isolated move by this particular investor.
The details
According to the 13F filing, Aster Capital Management DIFC Ltd sold 3,735 shares of IDEXX Laboratories during the third quarter, leaving the firm with a much smaller position of 195 shares valued at $125,000. The filing does not provide any additional context or rationale for the portfolio change.
- Aster Capital Management DIFC Ltd reduced its IDEXX Laboratories position during the 3rd quarter of 2026.
The players
Aster Capital Management DIFC Ltd
An institutional investor that has reduced its stake in IDEXX Laboratories by 95% as of the most recent 13F filing.
IDEXX Laboratories, Inc.
A global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets.
The takeaway
While the reasons behind Aster Capital's portfolio move are unclear, this reduction in a major institutional investor's IDEXX Laboratories position is worth monitoring to see if it signals a broader shift in sentiment around the stock.
